Bitter melon for diabetes is one of the most widely used herbal approaches to blood sugar across Asia, India, Africa, and the Caribbean — a vegetable so traditional that it is consumed daily in many households where diabetes runs in the family. The plant contains multiple compounds with hypothesized glucose-lowering action — charantin, vicine, and polypeptide-p. Clinical trial evidence is mixed, and the American Diabetes Association does not recommend it. Important safety considerations include pregnancy contraindication and a hazard for people with G6PD deficiency. This guide walks through the biology, the evidence, dosing, side effects, and the ADA position.
What Bitter Melon Is
Momordica charantia is a tropical and subtropical vine in the gourd family (Cucurbitaceae) — related to cucumber, squash, and pumpkin. Common names:
- English: bitter melon, bitter gourd, balsam pear, balsam apple
- Hindi: karela
- Chinese: ku gua (苦瓜)
- Japanese/Okinawan: goya (ゴーヤー)
- Spanish: cundeamor, melón amargo
- Tagalog: ampalaya
The fruit is the main edible and medicinal part — a bumpy green gourd ranging from a few inches to a foot long. It is extremely bitter, even when young; salt-soaking and parboiling are common techniques to reduce bitterness before cooking. The seeds and pith are usually removed.
Active Compounds
- Charantin: a mixture of steroidal saponins (mainly two stigmastadiols); proposed insulin-mimetic and beta-cell supportive
- Vicine: a glycoalkaloid (pyrimidine glycoside); precursor of divicine; causes hemolysis in G6PD-deficient individuals
- Polypeptide-p (p-insulin): a 166-amino-acid polypeptide with insulin-like effects in animal studies (when injected)
- Momordicins: bitter triterpenoid glycosides
- Cucurbitacins: bitter triterpenoids; some have anticancer claims in cell culture
- Conjugated linolenic acid: in seed oil; may affect PPAR signaling
- Vitamins and minerals: vitamin C, folate, potassium, magnesium
Mechanisms
| Mechanism | Evidence level | Notes |
|---|---|---|
| Charantin insulin-mimetic effect | Animal studies | Reduces glucose in diabetic rats and rabbits |
| Polypeptide-p hypoglycemic action | Animal data — injectable form | Oral bioavailability of polypeptide unclear |
| Increased glucose uptake in muscle | Cell culture; some animal | Via AMPK or insulin-independent mechanisms |
| Reduced hepatic gluconeogenesis | Animal data | Mechanism partially overlapping with metformin |
| Inhibition of intestinal disaccharidases | In vitro | Slight slowing of carbohydrate digestion |
| Beta-cell preservation | Animal data | Streptozotocin-diabetic models |
| PPAR-gamma activation (CLA) | Seed oil; preclinical | Similar concept to thiazolidinediones |
Evidence Summary
| Study | Population | Dose / form | Duration | Finding |
|---|---|---|---|---|
| Welihinda 1986 | T2D adults (n=18) | 100 mL juice / day | 3 weeks | Improved glucose tolerance |
| Srivastava 1993 | T2D Indian adults | 200 mL juice or 5 g dried powder | 3 weeks | Fasting glucose reduced |
| Tongia 2004 | T2D adults on metformin / glipizide | 2 g fruit powder / day | 1 week | Modest glucose improvement |
| Dans 2007 (Philippines RCT) | T2D adults (n=40) | 3 g/day capsules | 3 months | No significant A1C effect |
| Fuangchan 2011 (J Ethnopharmacol) | Newly diagnosed T2D (n=143) | 500 mg, 1 g, or 2 g/day vs metformin 1 g/day | 4 weeks | Bitter melon 2 g lowered fructosamine modestly; metformin clearly superior |
| Ooi 2012 (Cochrane review) | Pooled trials | Various | Various | Insufficient evidence; trials methodologically weak |
| Yin 2014 (meta-analysis) | Pooled trials | Various | Various | Modest but inconsistent glucose effects |
The pattern: small open-label studies show modest benefit; the more rigorous trial (Dans 2007 RCT) was negative; the head-to-head trial against metformin (Fuangchan 2011) found bitter melon clearly inferior. The Cochrane review concluded the evidence does not support routine use.
Typical Dosing in Trials
| Form | Dose | Notes |
|---|---|---|
| Fresh juice | 50 to 100 mL daily, empty stomach | Traditional Ayurvedic / Asian preparation |
| Dried fruit powder | 2 to 5 g/day divided | Capsules or mixed with water |
| Standardized extract | 200 to 600 mg, 2 to 3 times daily | Variable standardization |
| Fresh fruit (culinary) | 50 to 200 g/day cooked | Lower active compound dose; lower side effect risk |
| Bitter melon tea | 1 to 3 cups/day | Lowest dose form |
This describes trial and traditional dosing, not a recommendation. Talk to your healthcare provider before starting any supplement.
Side Effects and Safety Concerns
| Concern | Detail |
|---|---|
| GI: abdominal pain, diarrhea | Common at higher doses |
| Hypoglycemia | Possible — especially with insulin or sulfonylureas; rare cases of severe hypoglycemia and coma in children |
| Headache | Common at higher doses |
| Liver enzyme elevation | Rare |
| Favism / hemolytic anemia | In G6PD-deficient individuals — vicine causes the same syndrome as fava beans |
| Spontaneous abortion / preterm labor | In pregnancy — abortifacient activity; AVOID |
| Reduced fertility | Animal data — bitter melon seeds may impair spermatogenesis |
| Allergic reaction | Uncommon |
Drug Interactions
- Insulin: additive hypoglycemia — monitor closely
- Sulfonylureas: additive hypoglycemia
- Other glucose-lowering medications: theoretically additive
- Antihypertensives: bitter melon may have modest blood pressure effects
- CYP3A4 substrates: limited evidence of cytochrome P450 effects
The G6PD Warning
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzyme defect — affecting an estimated 400 million people globally, with the highest prevalence in African, Mediterranean, Middle Eastern, and South Asian populations. In G6PD-deficient red blood cells, oxidative stress can trigger hemolysis (red blood cell destruction) leading to anemia, jaundice, and dark urine.
Vicine in fava beans triggers the same syndrome (“favism”) and bitter melon seeds contain vicine. There are reports of acute hemolytic episodes in G6PD-deficient individuals after consuming bitter melon seeds or seed-containing products. The fruit pulp has less vicine than the seeds but the safety margin in G6PD-deficient individuals is unclear.
If you have G6PD deficiency, or are of high-prevalence ancestry and have not been tested, avoid bitter melon supplementation. Standard culinary use of small amounts of well-cooked deseeded fruit is generally lower risk but still warrants caution.
Pregnancy Contraindication
Bitter melon has documented abortifacient activity in animal studies and historical use as a folk emmenagogue. Effects include:
- Uterine contraction stimulation
- Possible disruption of implantation
- Anti-fertility effects in animal models
Medicinal doses (juice, powder, extract) should be avoided throughout pregnancy. Culinary use of small amounts of cooked fruit is variably considered — many Asian and Indian women avoid bitter melon entirely during pregnancy as a traditional precaution.
ADA Position
The American Diabetes Association Standards of Care does not endorse bitter melon for diabetes management, citing insufficient evidence. The 2012 Cochrane review concluded that there is no convincing evidence to support its use, and the only head-to-head trial against metformin found bitter melon clearly inferior. The National Center for Complementary and Integrative Health takes a similar view.
Cost and Forms
- Fresh bitter melon (Asian/Indian groceries): 1 to 4 dollars per pound
- Bitter melon powder capsules: 10 to 25 dollars per month
- Bitter melon tea bags: 5 to 15 dollars per box
- Liquid extract / tincture: 15 to 30 dollars per bottle
- Standardized extract supplements: 20 to 40 dollars per month
Practical Considerations
- Culinary use of bitter melon as a vegetable is the lowest-risk form — stir-fry, soup, stuffed bitter melon
- Remove seeds and inner pith before cooking — this reduces vicine and bitterness
- Salt-soak and parboil for 5 minutes to reduce bitterness
- If supplementing, start at a low dose (500 mg fruit powder daily) and monitor glucose
- Get tested for G6PD deficiency before starting medicinal doses if you are of high-risk ancestry
- Avoid completely during pregnancy and breastfeeding
- Stop 2 weeks before any planned surgery
Who Might Try It
- Adults with type 2 diabetes interested in a culturally relevant culinary food
- People who already eat bitter melon as a vegetable and want to discuss higher therapeutic intake
- Those who have been tested and confirmed not to have G6PD deficiency
Who Should Avoid
- Pregnant or trying-to-conceive women
- People with G6PD deficiency
- Children
- People on insulin or sulfonylureas without close monitoring
- People with liver disease
- People scheduled for surgery
Related Reading
See our companion guides on gymnema sylvestre for diabetes and fenugreek for diabetes, our overview of diabetes treatment, and our broader resource on diet and nutrition for diabetes.
The Bottom Line
Bitter melon (Momordica charantia) is a vegetable and traditional medicine used across Asia, India, Africa, and the Caribbean for diabetes — with multiple bioactive compounds including charantin, vicine, and polypeptide-p. The clinical evidence is mixed and generally weak — small trials suggest A1C reductions of around 0.25 to 0.5 percent, the 2012 Cochrane review found insufficient evidence, and the head-to-head Fuangchan trial showed metformin clearly superior at 2 g/day bitter melon. The American Diabetes Association does not recommend it. Three safety issues deserve particular attention: pregnancy contraindication (abortifacient), G6PD-deficient individuals (vicine-induced hemolysis), and additive hypoglycemia with insulin or sulfonylureas. Culinary use of cooked deseeded bitter melon as a vegetable is generally low-risk; medicinal doses of juice, powder, or extract require more caution. Talk to your healthcare provider before starting any supplement, do not stop or reduce prescribed diabetes medication, and be aware that bitter melon is not a replacement for proven diabetes therapies.
